Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 80Rectal Neoplasms 40Colonic Neoplasms 34Pancreatic Neoplasms 27Stomach Neoplasms 22Carcinoma, Hepatocellular 21Breast Neoplasms 21Esophageal Neoplasms 20Neoplasm Metastasis 18Nasopharyngeal Carcinoma 15Esophageal Squamous Cell Carcinoma 13Neoplasms 7Head and Neck Neoplasms 7Liver Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Squamous Cell 5Anus Neoplasms 5Adenocarcinoma Of Esophagus 5Nasopharyngeal Neoplasms 4Inflammatory Breast Neoplasms 4Cholangiocarcinoma 4Recurrence 3Gallbladder Neoplasms 3Breast Neoplasms, Male 3Bile Duct Neoplasms 3Solid Tumors 2Ovarian Neoplasms 2Neutropenia 2Neoplasms, Unknown Primary 2Laryngeal Neoplasms 2

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × Fluorouracil × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡